Tumor Immunology Biotech Firm Virongin Raises $62M

Virongin, a Chinese biotech firm, has recently completed a US$62 million series C financing. This round of financing was jointly led by CDH Investment and SDIC China Merchants, and was jointly funded by KIP, Pan Lin Capital, Peking University Guanghua Canadian Alumni Association, Leading Capital, Xiaoxi Holdings and other institutions. BMD Capital acted as the […]

Tumor Immunology Biotech Firm Virongin Raises $62M comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.

Read the original article: China Money Network